Non-small cell lung cancer (NSCLC) EGFR-TK positive

Indication for Gefitinib

Population group: Suitable for both men and women, only adults (18 years old or older)

Gefitinib is indicated as monotherapy for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating mutations of EGFR-TK.

For this indication, competent medicine agencies globally authorize below treatments:

250 mg once a day

Route of admnistration


Defined daily dose

250 - 250 mg

Dosage regimen

From 250 To 250 mg once every day

Detailed description

The recommended posology of gefitinib is one 250 mg once a day. If a dose is missed, it should be taken as soon as the patient remembers. If it is less than 12 hours to the next dose, the patient should not take the missed dose. Patients should not take a double dose (two doses at the same time) to make up for a forgotten dose.

Dosage considerations

It may be taken orally with or without food, at about the same time each day.

Active ingredient

Gefitinib is a selective small molecule inhibitor of the epidermal growth factor receptor tyrosine kinase and is an effective treatment for patients with tumours with activating mutations of the EGFR tyrosine kinase domain regardless of line of therapy. No clinically relevant activity has been shown in patients with known EGFR mutation-negative tumours.

Read more about Gefitinib

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner